Citations

Clear

6729 citation(s) found for "Li, Mark".

Auricular neuromodulation after rotator cuff repair: insights from a pilot feasibility experience
Ligocki, Mariusz , Ligocki, Anna Maria, Rodosky, Mark W. , Chelly, Jacques E., Orebaugh, Steven L. , Ligocki, Mariusz , Ligocki, Mariusz

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107450

10.1136/rapm-2025-107450 | PMID 41558775 Get It

Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia
Montalban-Bravo, Guillermo, Wu, Chong , Rodríguez‐Sevilla, Juan José , Wei, Yue , Chien, K., Bouligny, Ian , Kanagal‐Shamanna, Rashmi , Li, Ziyi , Natu, Anuya , Bazinet, Alexandre , Hammond, Danielle E., Bataller, Alex, Borthakur, Gautam, Short, Nicholas J., DiNardo, Courtney D., Kadia, Tapan M., Ravandi, Farhad, Daver, Naval, Pemmaraju, Naveen, Jabbour, Elias, Issa, Ghayas C., Wang, Sa A., Patel, Keyur P. , Tang, Guilin, Medeiros, L. Jeffrey, Finke, Christy M. , Al‐Kali, Aref , Alkhateeb, Hassan, Gangat, Naseema, Mangaonkar, Abhishek A., Román, David , Arenillas, Leonor , Tefferi, Ayalew, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Calvo, Xavier , Patnaik, Mrinal M. , Loghavi, Sanam, Kantarjian, Hagop M. , Bravo, Guillermo Montalban , Chien, Kelly , Gurney, Mark , Bazinet, Alexandre , Hammond, Danielle , Bataller, Alex , Borthakur, Gautam , Short, Nicholas , DiNardo, Courtney , Kadia, Tapan M , Ravandi, Farhad , Daver, Naval , Pemmaraju, Naveen , Jabbour, Elias , Issa, Ghayas , Wang, Sa A , Patel, Keyur P , Tang, Guilin , Medeiros, L Jeffrey , Lasho, Terra L , Finke, Christy M , Al-Kali, Aref , Csizmar, Clifford , Alkhateeb, Hassan B , Gangat, Naseema , Mangaonkar, Abhishek A. , Roman-Bravo, David , Arenillas, Leonor , Tefferi, Ayalew , Kantarjian, Hagop , Garcia-Manero, Guillermo , Calvo, Xavier , Patnaik, Mrinal , Loghavi, Sanam , Kanagal-Shamanna, Rashmi , Rodríguez-Sevilla, Juan José , Montalban‐Bravo, Guillermo , Chien, Kelly S. , Gurney, Mark E. , Hammond, Danielle , Borthakur, Gautam , Short, Nicholas J. , DiNardo, Courtney D. , Kadia, Tapan M. , Daver, Naval , Pemmaraju, Naveen , Jabbour, Elias , Wang, Sa A. , Tang, Guilin , Medeiros, L. Jeffrey , Lasho, Terra L. , Csizmar, Clifford M. , Alkhateeb, Hassan B. , Gangat, Naseema , Mangaonkar, Abhishek A. , Tefferi, Ayalew , Garcia‐Manero, Guillermo , Loghavi, Sanam

Mayo Clinic

Blood Cancer Discovery | January 26, 2026 | Volume: 7 | Issue: 3 | Pages: 414-430

10.1158/2643-3230.bcd-25-0264 | PMID 41587375 Get It

Abstract Recent updates to monocyte count thresholds recognize oligomonocytic chronic myelomonocytic leukemia (OM-CMML) as an early form of CMML. However, the clinical validity of these changes remains uncertain without incorporating biological and genomic factors. In this study, we analyzed a cohort of 911 patients (249 with OM-CMML, 359 with overt CMML, and 303 with myelodysplastic syndromes) using unsupervised clustering to evaluate the role of genomic determinants in refining CMML diagnosis. Our findings show that CMML molecular signatures (biallelic TET2 mutations or SRSF2-TET2 comutations) are linked to a distinct transcriptome, monocytic bias, classical monocytosis, and a higher risk of progression to overt CMML in OM-CMML cases. We developed a weighted genomic model and diagnostic workflow showing that combining genomic signatures with bone marrow monocyte frequencies in OM-CMML more accurately predicts progression to overt CMML. These findings support integrating genomic determinants and our clinic-ready diagnostic workflow into the CMML diagnostic framework to improve accuracy. Significance: Through comprehensive clinical and genomic profiling of a large patient cohort, alongside immunophenotypic and transcriptional cellular analyses, this study provides evidence that incorporating genomic determinants into the diagnostic criteria for OM-CMML improves diagnostic accuracy and refines the identification of early-stage CMML, thereby preventing misclassification.
Antiresorptive Consolidation After Osteoanabolic Therapy
Badour, Sanaa , Takagi, Mark, Everhart, Alexander , Parimi, Joseph Theressa Nehu, Mandic, Pinar Karaca, McCoy, Rozalina G. , Herrin, Jeph , Karaca‐Mandic, Pinar , Brito, Juan P.

Mayo Clinic

JAMA Internal Medicine | January 26, 2026 | Volume: 186 | Issue: 3 | Pages: 379

10.1001/jamainternmed.2025.7530 | PMID 41587062 Get It

This cohort study examines the clinical implementation of timely consolidation with antiresorptive therapy to preserve bone mineral density gains and reduce fracture risk.
Economic Evaluation of Tympanostomy Tube Placement
Brendes, Keith D. , Beckerman, Chase, Ritchey, Andrew , Page, Nathan C., Gerber, Mark E. , Ritchey, Andrew, Page, Nathan

Mayo Clinic

The Laryngoscope | January 24, 2026 | Volume: 136 | Issue: 6 | Pages: 2765-2768

10.1002/lary.70391 | PMID 41578617 Get It

ABSTRACT Objectives The purpose of this study is to compare the economics of in‐office tympanostomy tube placement using single use devices versus standard placement in the operating room (OR). Methods A retrospective chart review was completed for all pediatric patients who underwent in‐office tympanostomy tube placement (CPT 69433) along with insurance and date matched patients with placement in the OR (CPT 69436) between 12/1/21–3/1/24. Financial data were compared among the public vs. private insurance cohorts using the Wilcoxon rank‐sum test with a two‐sided significance level of 5%. Results One hundred and thirty‐six in‐office patients were identified, 102 private versus 34 public, and compared with 136 insurance and date matched OR patients. The average total payment for both privately insured patients, $647.14 in‐office versus $6873.45 in the OR, and publicly insured patients, $312.74 in‐office versus $2656.34 in the OR, was statistically significant. The average insurance payment for both privately insured patients, $301.58 in‐office versus $5445.73 in the OR, and publicly insured patients, $310.63 in‐office versus $2258.65 in the OR, was statistically significant. For the patient payment, public insurance usually has 0 copay and is therefore excluded. The patient payment of the private insurance cohort, $308.30 in‐office versus $670.61 in the OR, was not found to be statistically significant. Conclusion As expected, this study demonstrates significant reductions in overall cost with in‐office tympanostomy tube placement even with the added cost of single‐use devices compared to the standard placement in the OR, particularly for insurance companies, suggesting the potential benefit of providing reimbursement for these devices. Level of Evidence N/A.
Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinoma
Kuipers, Hendrien , Carlson, Danielle M. , Jessen, Erik , Abeynayake, Aushinie, Mun, Dong-Gi, Tomlinson, Jennifer L. , Abdelrahman, Amro M. , Werneburg, Nathan W., Li, B. , Ozmert, Enis H., Conboy, Caitlin B. , Truty, MD Mark, Pandey, Akhilesh, Ilyas, Sumera, Gores, Gregory J., Smoot, Rory L., Mun, Dong‐Gi , Mun, Dong-Gi , Tomlinson, Jennifer , Abdelrahman, Amro M , Borad, Mitesh J , Truty, Mark J , Ilyas, Sumera Irie , Gores, Gregory J. , Smoot, Rory L , Jessen, Erik , Conboy, Caitlin B , Carlson, Danielle Marie , Sample, Jack W. , Borad, Mitesh J. , Truty, Mark J. , Ilyas, Sumera I. , Gores, Gregory J.

Mayo Clinic

No container title available | January 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.21.699926 | PMID 41648234 Get It

ABSTRACT The limited efficacy of current therapies against cholangiocarcinoma (CCA) necessitates the development of novel treatment strategies. Src family kinases (SFKs) contribute significantly to tumor progression and resistance in CCA. Therefore, we investigated the novel, first-in-class SFK ‘OFF’ inhibitor NXP900 in diverse preclinical CCA models, including those with acquired resistance. This study evaluated the therapeutic effects of NXP900 and detailed adaptive molecular responses to SFK inhibitor therapy. We also aimed to identify biomarkers predictive of drug sensitivity using integrated multiomic profiling and develop strategies to overcome resistance. NXP900 inhibited YAP activity through direct inhibition of tyrosine phosphorylation and indirect activation of the Hippo pathway via LATS. These effects were associated with decreased tumor cell viability in CCA cell lines and several in vivo models. Notably, IDH -mutant patient-derived xenograft CCA models were particularly sensitive to NXP900. NXP900 also synergized with gemcitabine/cisplatin chemotherapy, enhancing antitumor efficacy in both in vitro and in vivo models. Multiomic analyses combining transcriptomics, global proteomics, and phosphoproteomics identified molecular features associated with primary response and acquired resistance. IL13RA-AKT signaling was upregulated in resistant models; NXP900 sensitivity could be restored with AKT or IL13RA2 inhibition. Together, these findings demonstrate the therapeutic potential of NXP900 as a novel YAP inhibitor in CCA and support further investigation in a clinical trial. Graphical Abstract
Thalamic Neuromodulation: New Frontiers
Hsu, Janine , Ali, Rushna , Englot, Dario J. , Muh, Carrie R. , Richardson, R. Mark, Rammo, Richard , Englot, Dario J , Muh, Carrie R , Air, Ellen L. , Richardson, Robert Mark

Mayo Clinic

Epilepsy Currents | January 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15357597261416388 | PMID 41584905 Get It

Thalamic neuromodulation for drug-resistant epilepsy has evolved from ablative thalamotomy to network-guided deep-brain stimulation (DBS) and responsive neurostimulation (RNS). Currently, the only Food and Drug Administration-approved DBS target is the anterior thalamic nucleus, which provides substantial and durable seizure reduction, particularly in limbic and temporal epilepsies. There is growing evidence that the centromedian and pulvinar nuclei are implicated in generalized, multifocal, and posterior neocortical epilepsies. Advanced imaging, probabilistic atlases, and connectomics can be used to refine targeting; however, they are limited by patient specificity, acquisition burden, and interatlas variability. Thalamic stereoelectroencephalography may clarify potential neuromodulation target selection by characterizing ictal recruitment, network dynamics, and biomarkers. Although DBS and RNS each have unique benefits, no modality has demonstrated superior. Pediatric data are heterogeneous and scarcer, but seizure reduction and safety profiles are similar to adults. Further studies are needed to optimize neuromodulation target selection and programming paradigms.
Larger-Volume Silicone Breast Implants Are Safe in Breast Reconstruction: The Athena Multicenter Prospective Study of 400 Patients
Garvey, Patrick B., Larsen, A. Denise, Skoracki, Roman J. , Djohan, Risal S., Migliori, Mark R., Tenenbaum, Marissa M., Friedman, Jeffrey D., Serletti, Joseph M., Rebecca, Alanna M. , Kane, William J. , Djohan, Risal , Tenenbaum, Marissa M.

Mayo Clinic

Plastic & Reconstructive Surgery | January 22, 2026 | Volume: 158 | Issue: 1 | Pages: 10-23

10.1097/prs.0000000000012840 | PMID 41568948 Get It

Background: For women in the United States desiring implant-based breast reconstruction, the maximum volume of commercially available silicone breast implants has, to date, been 800 cc. The authors evaluated the safety of Mentor larger-size MemoryGel Ultra-High Profile breast implants (≥930 cc) in women undergoing postmastectomy breast reconstruction. Methods: This 10-year, multicenter, open-label, prospective, investigational study assessed the safety and effectiveness of larger-volume implants in women undergoing postmastectomy 2-stage primary or revision reconstruction. Three-year Kaplan-Meier curves and multivariable Cox regression analyzed the association between patient and treatment characteristics and surgical outcomes. The BREAST-Q was used to assess effectiveness at 3 years. Results: A total of 400 women were enrolled (225 primary and 175 revision reconstruction). Mean body mass index was 35.8 kg/m 2 ; 81% had a body mass index greater than or equal to 30 kg/m 2 . At 3 years, the cumulative incidence of postoperative complications (excluding rupture) was 63.0% (95% confidence interval, 58.1% to 67.9%). The reoperation rate was 24.5% (95% CI, 20.4% to 29.1%), and the explantation rate was 15.8% (95% CI, 23.5% to 19.9%). Independent predictors of complications included radiation therapy and a history of smoking. There were no significant associations between postoperative complications and implant volume greater than or equal to 1135 cc or less than 1135 cc. BREAST-Q scores at year 3 showed significant improvements from baseline in Satisfaction with Breasts, Psychosocial Well-Being, Sexual Well-Being, and Physical Well-Being (all P < 0.0001). The mean score for Satisfaction with Outcome was 79.9. Conclusions: These 3-year results demonstrate that larger-volume silicone breast implants represent a safe and effective option for patients with larger breasts who are requesting postmastectomy implant-based reconstruction.
Core outcomes in nerve surgery: development of a core outcome set for lateral femoral cutaneous neuropathy
Wilson, Thomas J., Ali, Zarina S., Desai, Ketan, Garozzo, Debora, Guedes, Fernando, Heinen, Christian P. G., Hong, Jennifer , Jacques, Line G., Jitpun, Ekkapot , Kretschmer, Thomas , Mahan, Mark A., Midha, Rajiv, Puffer, Ross C. , Rasulic, L., Ray, Wilson Z., Rizk, Elias , Rodriguez-Aceves, Carlos A., Shapira, Yuval, Spinner, Robert J., Zager, Eric L. , Wilson, Thomas J. , Ali, Zarina S. , Davis, Gavin A , Dengler, Nora F. , Guedes, Fernando , Heinen, Christian , Jacques, Line , Mahan, Mark A , Midha, Rajiv, Pondaag, Willem , Rasulić, Lukas , Ray, Wilson Z. , Rodríguez-Aceves, Carlos Alberto , Saadeh, Yamaan S. , Socolovsky, Mariano , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 5 | Pages: 1224-1232

10.3171/2025.8.jns251142 | PMID 41569664 Get It

OBJECTIVE Core outcome sets (COSs) are needed to promote data consistency across studies as well as data synthesis and comparability. The aim of the current study was to use a modified Delphi process to develop a COS for lateral femoral cutaneous neuropathy (LFCN), hereafter COS-LFCN. METHODS A 5-stage approach was used to develop the COS-LFCN: 1) consortium development, 2) literature review to identify potential outcome measures, 3) Delphi survey to develop consensus on outcomes for inclusion, 4) Delphi survey to develop definitions, and 5) consensus meeting to finalize the COS and definitions. This study followed the Core Outcome Set - STAndards for Development, (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 25 participants, all neurological surgeons, representing 14 countries. The final COS-LFCN consisted of 41 factors and outcomes covering domains of demographics, diagnostics, patient-reported outcomes, motor/sensory outcomes, and complications. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 12 months, with the consensus optimal time points for assessment being preoperatively and 3, 6, and 12 months postoperatively. CONCLUSIONS The COINS Consortium developed a consensus COS for LFCN and provided definitions, methods of implementation, and time points for assessment. The COS-LFCN should serve as the minimum data to be collected in all future neurosurgical studies on LFCN. Incorporation of this COS will help improve consistency in reporting, data synthesis and comparability, and minimize outcome reporting bias.
Early graft failure after adult living donor liver transplantation: A multicenter risk analysis and development of the early allograft failure in living donor liver transplantation (EAGLE-LDLT) model
Li, Zhihao, Centonze, Leonardo , Raptis, Dimitri , Marquez, Kris Ann Hervera , Rammohan, Ashwin, Gunasekaran, Vasanthakumar , Hong, Suyoung , Chen, I Lun, KIM, Jongman , Hsu, Shih-Chao , Akamatsu, Nobuhisa, Shaked, Oren, Genedy, Lara, Dutkowski, Philipp , Nadalin, Silvio, Boehnert, Markus U, Mathur, Abhishek, Emond, J., Testa, Giuliano, Olthoff, Kim, Taner, Timucin, Wong, Tiffany CL, Hasegawa, Kiyoshi, Balci, D., Cattral, Mark, Sapisochin, G., Selzner, Nazia, Jeng, Long-Bin, Chen, Chao-Long, Suh, Kyung-Suk, Rela, Mohamed, Broering, Dieter, Clavien, Pierre-Alain, Kim, Jong Man , Raptis, Dimitri Aristotle , Li, Zhihao , Hong, Su young , Chen, I. , Centonze, Leonardo , Li, Zhihao , Rammohan, Ashwin , Chen, Itsuko Chih-Yi , Kirimker, Elvan Onur , Akamatsu, Nobuhisa , Shaked, Oren , Finotti, Michele , Yeow, Marcus , Nadalin, Silvio , Boehnert, Markus U , Polak, Wojciech G , Bonney, Glenn K , Samstein, Benjamin , Emond, Jean C , Testa, Giuliano , Olthoff, Kim M , Heimbach, Julie K , Taner, Timucin , Wong, Tiffany C L , Balci, Deniz , Cattral, Mark , Sapisochin, Gonzalo , Selzner, Nazia , Jeng, Long-Bin , Joh, Jae-Won , Chen, Chao-Long , Suh, Kyung-Suk , Di Sandro, Stefano , Rela, Mohamed , Broering, Dieter , Clavien, Pierre-Alain , Akamatsu, Nobuhisa , Shaked, Oren , Boehnert, Markus , Polak, Wojciech G. , Mathur, Abhishek , Samstein, Benjamin , Emond, Jean C. , Testa, Giuliano , Heimbach, Julie K. , Taner, Timuçin , Wong, Tiffany , Hasegawa, Kiyoshi , Cattral, Mark S. , Sapisochín, Gonzalo , Selzner, Nazia , Joh, Jae‐Won , Rela, Mohamed , Bröering, Dieter C. , Clavien, Pierre‐Alain

Mayo Clinic

Liver Transplantation | January 21, 2026 | Volume: 32 | Issue: 7 | Pages: 1027-1039

10.1097/lvt.0000000000000816 | PMID 41564353 Get It

Early allograft failure (EAF) after living donor liver transplantation (LDLT) remains a clinical challenge. Existing prediction models developed for deceased donor transplantation poorly apply to LDLT due to distinct surgical and physiological factors. This study identifies clinical determinants of EAF and develops an LDLT-specific prediction model. We conducted a multicenter retrospective cohort study from 17 high-volume LDLT centers (January 2016–December 2020) with external validation at a tertiary center in Saudi Arabia (January 2015–December 2022). The primary outcome was EAF (graft loss or patient death ≤90 d). Multivariable mixed-effects logistic regression identified preoperative/intraoperative risk factors. The EAGLE-LDLT model was constructed using postoperative laboratory values. Performance was compared against established models (EAD, MEAF, A2ALL) using ROC analysis and decision curve analysis. The development cohort included 2944 adult LDLT recipients (67.7% male; median age 55 y; median MELD 14) with a 5.5% EAF rate. External validation included 1020 recipients (median MELD 21, 6.7% EAF). Independent risk factors for EAF were MELD (OR 1.06, 95% CI 1.04–1.08), donor BMI (OR 1.05, 95% CI 1.00–1.10), portal vein thrombosis (OR 1.73, 95% CI 1.13–2.63), and hepaticojejunostomy (OR 1.58, 95% CI 1.06–2.36). The EAGLE-LDLT model incorporating peak ALT (>468 U/L), peak INR (>1.9), and bilirubin (>3.5 mg/dL) and INR (>1.3) at POD7, demonstrated superior discrimination (AUC=0.81) compared with MEAF (AUC=0.77, p =0.004), EAD (AUC=0.67, p <0.001), and A2ALL (AUC=0.65, p <0.001). EAGLE-LDLT achieved balanced sensitivity (75.0%) and specificity (73.7%), effectively stratifying patients into high-risk (15% of patients; 40.4% EAF incidence) and low-risk groups. Preoperative and intraoperative clinical factors predict EAF in LDLT. The EAGLE-LDLT model accurately identifies LDLT recipients at the highest risk for EAF postoperatively.
P0762 Defining Quality Pouch Surgery – A Critical Step Towards Centralization? International Consensus on Key Performance Indicators in Pouch Surgery (KPIPS) Study
Holubar, S, Soop, M., Poskus, T, Neary, P, Uchino, Tairin , Yang, S S, Adamina, M, Avellaneda, N L, Barnes, E, Brouquet, A, Brown, S R, Overstraeten, A De Buck Van, Buskens, C J, Chiorean, Michael , Clark, D, Cohen, B, Ouali, S El, Faiz, O D, Hahnloser, Dieter, Hancock, L, Herfarth, H, Johnston, M, Kayal, M, Laharie, D, Liberman, S, Loftus, E, Moeslein, G, Myrelid, P, Qazi, Taha , Raffals, L, Rubin, D T, Spinelli, A, Steinhagen, Emily , Verstock, Bram, Warusavitarne, J, Wexner, S, Winter, D, Group, KPIPS Study, Verstockt, Bram , Clark, David A. , Verstockt, B , Holubar, Stefan D. , Poškus, Tomas , Neary, Peter, Brouquet, Antoine , Overstraeten, Anthony de Buck van , Buskens, Christianne Johanna , Ouali, Sara El , Faiz, Omar , Fichera, Alessandro , Hahnloser, Dieter , Herfarth, Hans , Kayal, Maia , Laharie, David , Liberman, Sender A., Myrelid, Pär , Poylin, Vitaliy Y. , Raffals, Laura E. , Spinelli, A, Tozer, Phil J. , Wexner, Steven D

Mayo Clinic

Journal of Crohn’s and Colitis | January 21, 2026 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/ecco-jcc/jjaf231.943 Get It

Abstract Background Global data demonstrate an inverse relationship between hospital ileoanal pouch volume and adverse outcomes, highlighting the need for quality metrics for this technically demanding procedure.1-4 Currently, there are no standardised quality indicators to define high-quality pouch surgery. This study aimed to establish international consensus on key performance indicators (KPIs) in pouch surgery. Methods A modified Delphi process was conducted among an international, multidisciplinary panel of experts. Participants were identified through professional networks, literature review, and direct email invitation; additional participants recruited via a snowball sampling approach over one month. Candidate KPIs were generated from literature review and expert input across 5 domains. Each item was rated on a 9-point Likert scale (1 = not important, 9 = critically important); consensus was predefined as ≥ 80% of respondents rating an item 7–9. Items not reaching consensus were re-rated in a second round following anonymized group feedback. Results Round 1 included 312 participants from 37 countries. Demographics (Table 1): 53% were age 45 years, 35.2% were female, and included surgeons (68.6%) and gastroenterologists (31.1%). Most (76.6%) practice at academic or university hospitals, with a median of 11 (5–17) years in practise; 78.9% perform &gt;1 pouchoscopy per month, and 39.5% of surgeons perform 5 pouches/year. Respondents’ regions included North America (51%), Europe (26%), Oceania (9%), Asia (6%), Latin America (4%), and the Middle East/Africa (4%). Seven (18%) countries (Denmark, Lithuania, Malaysia, Norway, United Arab Emirates, Sweden, and Switzerland) reported pouch surgery is already centralised, while 70.6% agreed pouch centralisation should be implemented. Cost/logistics and professional autonomy were the most important barriers to centralisation, whereas capacity and training exposure were least important. Overall, 37/59 (62.7%) candidate KPIs reached consensus after Round 1. The Round 2 response rate was 61%, and 2 additional KPIs reached consensus (preop ileitis and long-term risk of pouchitis). Additionally, 14 of 25 (56%) informed consent items reached consensus, and 64% of respondents felt informed consent for pouch surgery requires 2 or more office visits. Consensus items were used to populate a KPIPS Checklist (Figure 1). Conclusion Through an international Delphi process, the KPIPS study identified a consensus-derived set of key performance indicators to measure quality in pouch surgery. These quality metrics provide a foundation for benchmarking outcomes and represent a critical step towards centralization and the development of designated pouch centres of excellence to improve global standards of care for pouch patients. References: 1. Worley GHT, Fearnhead NS, Brown SR, et al. Review of current practice and outcomes following ileoanal pouch surgery: Lessons learned from the ileoanal pouch registry and the 2017 ileoanal pouch report. Colorectal Dis 2018;20:913–22. 2. Giddings HL, Yang PF, Steffens D, Solomon MJ, Ng KS. Influence of hospital-level and surgeon factors on the outcomes after ileo-anal pouch surgery for inflammatory bowel disease: Systematic review. Br J Surg 2024;111. 3. Hoang CM, Maykel JA, Davids JS, et al. Distribution of elective ileal pouch-anal anastomosis cases for ulcerative colitis: A study utilizing the university health system consortium database. J Gastrointest Surg 2020;24:2613–9. 4. Moojen TB, Visser E, Reijntjes MA, et al. One-year stoma-free survival of ileoanal pouches for uc in european centers: The miracle project. Ann Surg Open 2025;6:e596. Conflict of interest: Prof. Holubar, Stefan: No conflict of interest Soop, Mattias: No conflict of interest Poskus, Tomas: No conflict of interest Neary, Peter: No conflict of interest Uchino, Tairin: No conflict of interest Yang, Song-soo: No conflict of interest Adamina, Michel: No conflict of interest Avellaneda, Nicolas Luis: No conflict of interest Barnes, Edward: No conflict of interest Brouquet, Antoine: No conflict of interest Brown, Steven Ross: No conflict of interest De Buck Van Overstraeten, Anthony: No conflict of interest Buskens, Christianne J.: No conflict of interest Chiorean, Michael: No conflict of interest Clark, David: No conflict of interest Cohen, Benjamin: No conflict of interest El Ouali, Sara: No conflict of interest Faiz, Omar Darius: No conflict of interest Fichera, Alessandro: No conflict of interest Hahnloser, Dieter: No conflict of interest Hancock, Laura: No conflict of interest Herfarth, Hans: No conflict of interest Johnston, Michael: No conflict of interest Kayal, Maia: No conflict of interest Laharie, David: No conflict of interest Liberman, Sender: No conflict of interest Loftus, Jr, Edward: No conflict of interest Moeslein, Gabriela: No conflict of interest Myrelid, Pär: No conflict of interest Poylin, Vitaliy: No conflict of interest Qazi, Taha: No conflict of interest Raffals, Laura: No conflict of interest Rubin, David T.: No conflict of interest Spinelli, Antonino: No conflict of interest Steinhagen, Emily: No conflict of interest Tozer, Philip: No conflict of interest Verstockt, Bram: No conflict of interest Warusavitarne, Janindra: No conflict of interest Wexner, Steven: No conflict of interest Winter, Desmond: No conflict of interest